INVO Fertility (NASDAQ:IVF – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($2.44) EPS for the quarter, FiscalAI reports. The business had revenue of $2.22 million during the quarter. INVO Fertility had a negative net margin of 116.29% and a negative return on equity of 85.54%.
INVO Fertility Stock Performance
NASDAQ:IVF opened at $2.40 on Tuesday. The company has a quick ratio of 0.67, a current ratio of 0.71 and a debt-to-equity ratio of 0.03. The company has a market cap of $1.51 million, a P/E ratio of -0.02 and a beta of 2.42. INVO Fertility has a fifty-two week low of $1.59 and a fifty-two week high of $91.60. The firm’s 50 day moving average is $10.16 and its two-hundred day moving average is $30.94.
Analyst Ratings Changes
Several equities analysts recently weighed in on the company. Wall Street Zen upgraded INVO Fertility to a “hold” rating in a research report on Saturday, August 29th. Weiss Ratings restated a “sell (e+)” rating on shares of INVO Fertility in a report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $320.00.
Check Out Our Latest Report on INVO Fertility
INVO Fertility Company Profile
INVO Fertility is a fertility-care company that develops and provides treatments for people seeking to build a family. Its offerings include fertility services through its clinics and the INVOcellĀ® system, a device and procedure that allows fertilization and early embryo development to take place inside the patient’s body. The company’s approach is an alternative to conventional in vitro fertilization, while also offering fertility care through its clinic operations. INVO Fertility has pursued growth by expanding its network of fertility centers in the United States and by making its technology available in international markets.
Read More
- Five stocks we like better than INVO Fertility
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
Receive News & Ratings for INVO Fertility Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Fertility and related companies with MarketBeat.com's FREE daily email newsletter.
